GH — Guardant Health Income Statement
0.000.00%
- $5.96bn
- $6.26bn
- $739.02m
- 48
- 21
- 83
- 49
Annual income statement for Guardant Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 287 | 374 | 450 | 564 | 739 |
Cost of Revenue | |||||
Gross Profit | 194 | 251 | 294 | 337 | 449 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 542 | 760 | 999 | 1,165 | 1,183 |
Operating Profit | -255 | -386 | -550 | -601 | -444 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -246 | -384 | -653 | -479 | -435 |
Provision for Income Taxes | |||||
Net Income After Taxes | -246 | -385 | -655 | -479 | -436 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -254 | -406 | -655 | -479 | -436 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -254 | -406 | -655 | -479 | -436 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.54 | -4.16 | -6.37 | -4.07 | -3.56 |